Endocrine Abstracts

Primary hypoparathyroidism is a rare condition. Contrary to other endocrine deficiencies treated with hormone replacement, recombinant parathyroid hormone (PTH) is not currently licensed for its treatment in Europe. Emerging evidence of efficacy and safety of recombinant PTH in treating resistant hypoparathyroidism will hopefully provide a new tool in managing this challenging condition.This is the case of a 45 year-old woman presenting with gradually wo...